RVPH News and Press, Reviva Pharmaceuticals Holdings Inc. From 05/13/24

CUPERTINO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous syste...

CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous syste...

2024-04-18 07:00:23 ET More on AbbVie AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie: Bulletproof Fundamentals CVS favors Humira copycats hurting AbbVie’s market share: Evercore Ab...

2024-04-15 14:15:36 ET More on Reviva Pharmaceuticals Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment Seeking Alpha’s Quant Rating on Reviva Pharmaceuticals Historical earnings data for Reviva Pharmaceuticals Fin...

2024-04-15 09:10:27 ET More on Reviva Pharmaceuticals Seeking Alpha’s Quant Rating on Reviva Pharmaceuticals Historical earnings data for Reviva Pharmaceuticals Financial information for Reviva Pharmaceuticals Read the full article on Seeking Alpha ...

- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia – - Topline data from 1-year open-labe...

– RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia – – Initiation of registrational RECOVER-2 trial expected in the second quarter of 2024;...

CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous sys...

2024-03-27 08:24:20 ET More on premarket gainers & stock Veritone: Not An AI Stock To Bank On Veritone, Inc. (VERI) Q4 2023 Earnings Call Transcript Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript Mesoblast gains as FDA backs regulatory plans fo...

2024-03-26 12:55:48 ET More on Mid-day movers & stocks. Veritone: Not An AI Stock To Bank On Veritone, Inc. (VERI) Q4 2023 Earnings Call Transcript Check-Cap jumps on Nobul AI business combination Veritone Non-GAAP EPS of -$0.16 in-line, revenue of $34.2M...